Prevalence of Dacrocytosis in Patients with Chronic Diseases: Splenomegaly is not Mandatory for Teardrop Cells Genesis

Rojas-Maya S1, Sarias-Cueto LA1, Perez-Diaz I2, Osorio-Landa HK3, Garcia-Martinez B4, Fagundo-Sierra R1, Rivera-Moscoso R2, Carrillo-Maravilla E2 and Laguna-Barcenas SC5

1Biological and Pharmaceutical Chemistry Central Laboratory, National Institute of Medical Science and Nutrition Salvador Zubiran, Tlalpan, Mexico
2Medicine Department, National Institute of Medical Science and Nutrition Salvador Zubiran, Tlalpan, Mexico
3School of Medicine, Monterrey Institute of Technology and Higher Education, Mexico
4Biological and Pharmaceutical Chemistry, Metropolitan University, Mexico
5Autonomous University of Queretaro, Queretaro, Mexico

Corresponding author: Perez-Diaz I, PhD, MD, Medicine Department, National Institute of Medical Science and Nutrition Salvador Zubiran, Tlalpan, Mexico, Tel: +52-55 87 09 00; E-mail: ivan.endocrino@gmail.com

Received date: March 10, 2016; Accepted date: April 13, 2016; Published date: April 20, 2016

Copyright: © 2016 Rojas-Maya S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Dacrocytes or “teardrop cells” are elongated red blood cells at one end forming a cell with the appearance of a tear drop and are of varying size. Dacrocytes are frequently observed in complete blood counts of patients with myeloproliferative disease, but can also be found in other systemic diseases in which their prevalence and clinical significance remains unknown.

Objective: To evaluate the prevalence and possible clinical significance of dacrocytes observed in the peripheral blood smear of patients with different systemic diseases.

Methods: This is a descriptive study that analyzed the peripheral blood smears of 35,086 patients in a tertiary care hospital, in search of dacrocytes, and correlating this finding with their clinical and biochemical profiles.

Results: Dacrocytes were intentionally sought in 35,086 peripheral blood smears. The observed prevalence of dacrocytosis was 1.4% (n=492 patients). No statistically significant relationship was established between dacrocytosis and the patients’ diagnoses, although there was a tendency to find dacrocytes in patients with cancer (CA) and systemic lupus erythematosus (SLE). Thus the presence of dacrocytes was not associated to the type of anemia or to the degree of renal dysfunction. Our results do not support the theory asserting that dacrocyte formation is a result of splenomegaly since only 28.5% of patients with this erythrocyte anomaly presented associated splenomegaly.

Conclusion: Dacrocytosis may be present, at a very low prevalence, in various systemic diseases. It is independent of the type of anemia and the degree of renal dysfunction. For the first time, splenomegaly is excluded as the only cause of dacrocytosis in peripheral blood smears.

Keywords: Dacrocyte; Systemic disease; Anemia; Renal dysfunction; Splenomegaly

Introduction

Dacrocytes or “teardrop cells” are elongated red blood cells at one end forming a cell with the appearance of a tear drop and are of varying size [1] (Figure 1).

These cells are most frequently observed in peripheral blood smears of patients with primary or secondary myelofibrosis with myeloid metaplasia, different types of anemia including iron deficiency, hemolytic, and megaloblastic anemia, as well as infiltrative disorders of the bone marrow such as leukaemia, lymphoma or metastatic solid neoplasms [2-4]. Furthermore, isolated reports have identified dacrocytes in patients with various systemic diseases associated to chronic renal dysfunction. However, information on the clinical implications of dacrocytosis in these systemic diseases has been practically non-existent and no study has evaluated its relationship with the presence of anemia and renal dysfunction. Whether the dacrocytosis in these patients is a result of concomitant splenomegaly, as it is believed nowadays, also remains unknown. The aim of this study was to determine the relationship between the prevalence of dacrocytosis and systemic diseases, and to correlate the presence of these teardrop cells with different types of anemia, renal dysfunction and splenomegaly in a tertiary care hospital.

Materials and Methods

This is a descriptive research study. Dacrocytes were sought in 35,086 peripheral blood smears of in-patients at a tertiary care hospital. Smears were obtained from the Hematology Laboratory between August and October 2013. The smears with identified dacrocytes were classified according to O’Connor’s criteria [5], as normal (0-1 dacrocytes/field), mild (2-5/field), moderate (6-15/field) and severe (>15/field). The following information was obtained from...
Kruskal-Wallis test. Meanwhile, correlations between variables were determined with the Pearson's or Spearman's correlation tests as appropriate.

The presence of anemia was established according to the hemoglobin concentration (<12 g/dL), and the red blood cell indices (mean corpuscular volume [MCV]: normal range 83.5 - 98 fL and mean corpuscular hemoglobin [MCH]: normal range 32.7-34.7 pg) and it was classified in: normocytic normochromic anemia (NNA), microcytic hypochromic anemia (MHA) and macrocytic normochromic anemia (MNA). Patients with myeloproliferative syndromes were excluded from the present study since dacrocytosis is a frequent finding in this population.

Statistical Analysis

All results are expressed as averages ± SD (standard deviation) or percentages. The comparison among groups was established with the Kruskal-Wallis test. Meanwhile, correlations between variables were determined with the Pearson's or Spearman's correlation tests as appropriate. The statistical analysis was performed with the Stata version 11.1 statistical software program for Windows; p values of <0.05 were considered statistically significant.

Results

Among the 35,086 analyzed smears, dacrocytes were identified in 492 (1.4%), from which 310 (63%) belonged to females and 182 (36.9%) to males. The average patient age was 46.2 ± 17 years (range: 16 to 93 years).

By analyzing the patients' diseases (n=492), we observed that the most frequent diagnoses encompassed all forms of cancer in 103 (20.9%), followed by systemic lupus erythematosus (SLE) in 97 (19.7%), liver cirrhosis in 75 (15.2%) and type 1 and 2 diabetes mellitus (DM) in 37 (7.5%) patients. In terms of dacrocytosis' degree, our findings exposed that 423 (86%) patients had mild dacrocytosis and only a small proportion, 69 (14%), had moderate dacrocytosis. No cases of severe dacrocytosis were detected. As a result, the correlation of the dacrocytosis' degree and the patients' different diagnoses established no statistically significant difference (p=0.06) (Table 1).

Table 1: Principal diagnoses of patients and degree of dacrocytosis (n=492).

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Mild (%)</th>
<th>Moderate (%)</th>
<th>Severe (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer</td>
<td>88 (17.9%)</td>
<td>15 (3.1%)</td>
<td>-</td>
</tr>
<tr>
<td>SLE</td>
<td>85 (17.3%)</td>
<td>12 (2.4%)</td>
<td>-</td>
</tr>
<tr>
<td>Liver cirrhosis</td>
<td>67 (13.6%)</td>
<td>8 (1.6%)</td>
<td>-</td>
</tr>
<tr>
<td>DM</td>
<td>32 (6.5%)</td>
<td>5 (1.0%)</td>
<td>-</td>
</tr>
</tbody>
</table>

The values are expressed in n (%). Percentages represent the proportion from the total of patients with dacrocytosis (n=492). There was no significant difference between groups (p=0.06). SLE: Systemic lupus erythematosus. DM: Type 1 and 2 diabetes mellitus.

Interestingly, from all patients with dacrocytosis (n=492), 467 (95%) presented anemia (Hb: 10.3 ± 1.9 g/dL): MHA was the most common form of anemia in 193 (39.2%) patients, followed by NNA in 172 (35%) patients, and MNA was the least prevalent in 102 (20.7%) patients. Only 25 (5.1%) patients did not have anemia. In all the anemia groups, mild dacrocytosis was predominantly observed (87.5% in MHA; 87.2% in NNA, and 79.4% in MNA) (p=0.78) (Table 2).

Table 2: Type of anemia and degree of dacrocytosis (n=492).

<table>
<thead>
<tr>
<th>Type of anemia</th>
<th>Mild (%)</th>
<th>Moderate (%)</th>
<th>Severe (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MHA</td>
<td>169 (34.4%)</td>
<td>24 (4.9%)</td>
<td>-</td>
</tr>
<tr>
<td>NNA</td>
<td>150 (30.5%)</td>
<td>22 (4.5%)</td>
<td>-</td>
</tr>
<tr>
<td>MNA</td>
<td>81 (16.5%)</td>
<td>21 (4.3%)</td>
<td>-</td>
</tr>
<tr>
<td>N</td>
<td>23 (4.7%)</td>
<td>2 (0.4%)</td>
<td>-</td>
</tr>
</tbody>
</table>

The values are expressed in n (%). Percentages represent the proportion from the total of patients with dacrocytosis (n=492). There was no significant difference between groups (p=0.78). MHA: microcytic hypochromic anemia. NNA: normocytic normochromic anemia. MNA: macrocytic normochromic anemia. N: No anemia.

To evaluate patients' renal function, serum creatinine values were obtained in 80.3% of the cases (n=395), from which 323 (85.4%) values were within the normal range (<1.3 mg/dL) and only 72 (14.6%) patients presented levels above reference values (≥1.3 mg/dL).

By using the Pearson's or Spearman's correlation tests, it was observed that there was no significant difference in terms of degree of dacrocytosis and serum creatinine values (p<0.05) (Table 3).

Table 3: Degree of dacrocytosis and serum creatinine values (n=395).

<table>
<thead>
<tr>
<th>Degree of Dacrocytosis</th>
<th>Serum Creatinine Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>0.78 (p=0.06)</td>
</tr>
<tr>
<td>Moderate</td>
<td>0.78 (p=0.06)</td>
</tr>
<tr>
<td>Severe</td>
<td>0.78 (p=0.06)</td>
</tr>
</tbody>
</table>

To evaluate patients' renal function, serum creatinine values were obtained in 80.3% of the cases (n=395), from which 323 (85.4%) values were within the normal range (<1.3 mg/dL) and only 72 (14.6%) patients presented levels above reference values (≥1.3 mg/dL).

Estimation of the glomerular filtration rate (MDRD), revealed that: 51.7% of patients were K/DOQI 1, 24.6% K/DOQI 2, 14.2% K/DOQI 3, 4.3% K/DOQI 4 and 5.3% were K/DOQI 5. No statistically significant linear relationship between the degree of dacrocytosis and renal dysfunction was found (rs=0.0136, p=0.2) (Table 3).

According to the imaging charts (n=491), only 140 (28.5%) patients presented splenomegaly, from which 88 (62.5%) had mild dacrocytosis and 52 (37.5%) had moderate dacrocytosis. By comparing of the
degree of dacrocytosis between patients with (n=140) and without splenomegaly (n=351), no statistically significant difference was observed (p=0.45).

**Table 3: Dacrocytosis in patients with renal dysfunction (n=395)**

**Discussion**

The presence of dacrocytes in blood counts is typically observed in patients with myeloproliferative disease, but its prevalence and clinical significance in other systemic diseases such as DM, chronic kidney disease (CKD), SLE and liver cirrhosis remain unknown.

As far as we know, this is the first large scale study addressing the clinical significance of dacrocytes in patients with various chronic diseases. The main pathological entities clearly related to dacrocytosis are myelophthisis and myeloproliferative disorders (polycythemia vera, myelofibrosis and essential thrombocythemia), all associated to splenomegaly.

Very few authors have reported the presence of dacrocytes in patients with different diseases from the mentioned above. After observing dacrocytes in patients with chronic disease, we thought that their presence could be a marker of a particular clinical situation. However, after reviewing those smears, the prevalence of dacrocytes was 1.4%, a much lower percentage than its prevalence in patients with CKD undergoing rheological changes that make them more liable to disintegration since they are also more prone to oxidative stress. This may contribute to decreased red blood cell survival, and increased deformity due to intracellular calcium accumulation leading to erythrocyte cell membrane abnormalities.

Anemia was present in 95% of our patients, although no association was established with the dacrocytosis’ degree. These cells have been reported in great numbers in a form of iron deficiency anemia characterized by its microcytic and hypochromic phenotype. Nevertheless, the mechanism through which erythrocytes adopt this pear shape remain unexplained. We must emphasize that 39.2% of our study population displayed this form of anemia but with a mild degree of dacrocytosis.

Although most authors agree that splenomegaly is one of the main mechanisms leading to these abnormally shaped erythrocytes, only 28.5% of our patients showed splenomegaly. There was no significant difference when comparing the degree of dacrocytosis between patients with and without splenomegaly, thus suggesting that other factors could possibly be participating in the genesis of deformed erythrocytes.

Since no direct correlation was observed between dacrocyte formation and splenomegaly, we suggest that the genesis of these cells may anatomically take place elsewhere in the body, and result from different factors to those previously proposed by other authors. Drugs, membrane glycation, or autoimmune states, among others may directly affect the integrity of erythrocyte membranes, increasing their tendency to deformity and decreasing their elasticity. Considering this property is a pivotal characteristic for their passage through narrow conduits such as blood vessels, the half-life of erythrocytes diminishes.

**Conclusion**

Dacrocytosis is a morphological erythrocyte abnormality which is not pathognomonic of any specific disease, as it could be found in different types of pathological entities. We observed that they do not correlate with different degrees of renal dysfunction and/or anemia.
Furthermore, splenomegaly is not a clinical characteristic directly responsible for the formation of dacrocytes.

**Conflict of Interest**

The authors do not have any conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Ethical Approval and Informed Consent**

The Institutional Review Board approved the study (approval number 1267). All procedures in human participants were performed according to the ethical standards of the institutional and/or national research committee, with the 1964 Helsinki declaration, and its later amendments or comparable ethical standards.

**Acknowledgements**

The authors would like to express their appreciation to Beckman Coulter de México S.A. de C.V. for providing them financial support for the publication.

**References**